SCHEDULE 13G/A: Long Focus Capital Management and Affiliates Disclose 8.0% Passive Stake in Adaptimmune Therapeutics PLC

Long Focus Capital Management, LLC, along with its affiliates and individuals John and Glenn Helmers, have disclosed a combined passive beneficial ownership of 8.0% in Adaptimmune Therapeutics PLC as of December 31, 2024.

Summary

• Long Focus Capital Management, LLC, an investment adviser, reported shared voting and dispositive power over 20,494,393 American Depositary Shares (ADS) of Adaptimmune Therapeutics PLC, representing 8.0% of the class.
• Long Focus Capital Master, Ltd., a Cayman Islands financial institution, reported shared voting and dispositive power over 13,354,858 ADS, representing 5.2% of the class.
• Condagua, LLC, a Delaware entity, reported shared voting and dispositive power over 7,139,535 ADS, representing 2.8% of the class.
• John Helmers, a U.S. citizen, reported shared voting and dispositive power over 20,494,393 ADS, representing 8.0% of the class, due to his control over Long Focus Capital Management, LLC and investment/voting power with respect to Condagua, LLC.
• Glenn Helmers, a U.S. citizen, reported shared voting and dispositive power over 7,139,535 ADS, representing 2.8% of the class, due to his control over Condagua, LLC.
• The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Adaptimmune Therapeutics PLC.
• Each American Depositary Share represents 6 Ordinary Shares of Adaptimmune Therapeutics PLC.

Sentiment

Score: 6

Explanation: The filing indicates a significant passive ownership stake by a group of investors, which can be interpreted as a positive signal of confidence in the issuer, Adaptimmune Therapeutics PLC. However, the document itself does not provide operational or financial performance data to assess overall sentiment.

Positives

• The disclosure of a significant passive stake by institutional investors and individuals may signal confidence in Adaptimmune Therapeutics PLC's long-term prospects.
• The aggregate beneficial ownership by the group, led by Long Focus Capital Management, LLC and John Helmers, reaching 8.0% indicates a substantial investment.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of a significant passive ownership stake by an investment firm and related individuals in a publicly traded biotechnology company. It does not provide specific industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by institutional investors and individuals may provide a degree of confidence or stability, indicating a substantial long-term interest in the company.

Key Dates

Keywords

ADAPTIMMUNE THERAPEUTICS PLC, American Depositary Shares, ADS, Beneficial Ownership, Schedule 13G, SEC Filing, Long Focus Capital Management, Institutional Investor, Passive Investment, Biotechnology